Mutations in the cell cycle checkpoint kinase 2 (CHEK2) tumor suppressor gene are
associated with multi‐organ cancer susceptibility including cancers of the breast and …

Background Differentiated thyroid carcinoma (DTC) originates from thyroid follicular
epithelial cells and belongs to a group of slowly progressing tumors with a relatively good …

A single founder allele of the CHEK2 gene has been associated with predisposition to
breast and prostate cancer in North America and Europe. The CHEK2 protein participates in …

The 1100delC mutation of the cell cycle checkpoint kinase 2 (CHEK2) gene confers an
increased risk for breast cancer, but the clinical impact of other CHEK2 gene variants …

We have recently shown that the CHEK2* 1100delC mutation acts as a low penetrance
breast cancer susceptibility allele. To investigate if other CHEK2 variants confer an …

A founder allele in the CHEK2 gene (1100delC) has been associated with an elevated risk
of breast cancer. This allele is responsible for the majority of CHEK2-associated breast …

Purpose CHEK2 is a cell cycle checkpoint regulator, and the CHEK2* 1100delC germline
mutation leads to loss of function and increased breast cancer risk. It seems plausible that …

Highlights•Compared phenotypes of founder and non-founder CHEK2 mutation carriers.•No
significant phenotypic differences were observed between founders and non …

The CHEK2 kinase is a tumor suppressor whose activation in response to DNA double‐
strand breaks contributes to cell cycle arrest or apoptosis. The c. 1100delC mutation is …

Background Mutations in the CHEK2 gene confer a moderately increased breast cancer risk.
The risk for female carriers of the CHEK2* 1100delC mutation is twofold increased. Breast …